Between the beginning of January 2020 and June 14, 2023, of the 1,134,641 deaths caused by COVID-19 in the United States, around 307,169 had occurred among those aged 85 years and older. This statistic shows the number of coronavirus disease 2019 (COVID-19) deaths in the U.S. from January 2020 to June 2023, by age.

Data on excess death during the coronavirus pandemic in young people.

As of April 26, 2023, around 27 percent of total COVID-19 deaths in the United States have been among adults 85 years and older, despite this age group only accounting for two percent of the U.S. population. This statistic depicts the distribution of total COVID-19 deaths in the United States as of April 26, 2023, by age group.

Among COVID-19 patients in the United States from February 12 to March 16, 2020, estimated case-fatality rates were highest for adults aged 85 years and older. Younger people appeared to have milder symptoms, and there were no deaths reported among persons aged 19 years and under.

Tracking the virus in the United States The outbreak of a previously unknown viral pneumonia was first reported in China toward the end of December 2019. The first U.S. case of COVID-19 was recorded in mid-January 2020, confirmed in a patient who had returned to the United States from China. The virus quickly started to spread, and the first community-acquired case was confirmed one month later in California. Overall, there had been approximately 4.5 million coronavirus cases in the country by the start of August 2020.

U.S. health care system stretched California, Florida, and Texas are among the states with the most coronavirus cases. Even the best-resourced hospitals in the United States have struggled to cope with the crisis, and certain areas of the country were dealt further blows by new waves of infections in July 2020. Attention is rightly focused on fighting the pandemic, but as health workers are redirected to care for COVID-19 patients, the United States must not lose sight of other important health care issues.

Effective June 28, 2023, this dataset will no longer be updated. Similar data are accessible from CDC WONDER (https://wonder.cdc.gov/mcd-icd10-provisional.html).

Deaths involving coronavirus disease 2019 (COVID-19) with a focus on ages 0-18 years in the United States.

The seven-day average number of COVID-19 deaths in the U.S. decreased significantly from April to July 2020, but it remained higher than in other countries. Seven-day rolling averages are used to adjust for administrative delays in the reporting of deaths by authorities, commonly over weekends.

The challenges of tracking and reporting the disease The U.S. confirmed its first coronavirus case in mid-January 2020 – the virus was detected in a passenger who arrived in Seattle from China. Since that first case, around 945 people have died every day from COVID-19 in the United States as of August 23, 2020. In total, the U.S. has recorded more coronavirus deaths than any other country worldwide. Accurately tracking the number of COVID-19 deaths has proved complicated, with countries having different rules for what deaths to include in their official figures. Some nations have even changed which deaths they can attribute to the disease during the pandemic.

Young people urged to act responsibly Between January and May 2020, case fatality rates among COVID-19 patients in the United States increased with age, highlighting the particular risks faced by the elderly. However, COVID-19 is not only a disease that affects older adults. Surges in the number of new cases throughout July 2020 were blamed on young people. The World Health Organization has urged young people not to become complacent, reminding them to maintain social distancing guidelines and take precautions to protect themselves and others.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152. Johnson AG, Linde L, Payne AB, et al. Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023. MMWR Morb Mortal Wkly Rep 2023;72:667–669.

As of January 11, 2023, the highest number of deaths due to the coronavirus in Sweden was among individuals aged 80 to 90 years old. In this age group there were 9,124 deaths as a result of the virus. The overall Swedish death toll was 22,645 as of January 11, 2023.

The first case of coronavirus (COVID-19) in Sweden was confirmed on February 4, 2020. The number of cases has since risen to over 2.68 million, as of January 2023. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Data on deaths in young people following COVID-19 vaccination registered by 16 February 2022.

Estimates of the risk of all-cause and cardiac death in the 12 weeks after vaccination or positive SARS-CoV-2 test compared with subsequent weeks for people aged 12 to 29 years in England using two sources of mortality data: ONS death registrations and deaths recorded in Hospital Episode Statistics. 8 December 2020 to 25 May 2022. Experimental Statistics.

Note: Data elements were retired from HERDS on 10/6/23 and this dataset was archived.

This dataset includes the cumulative number and percent of healthcare facility-reported fatalities for patients with lab-confirmed COVID-19 disease by reporting date and age group. This dataset does not include fatalities related to COVID-19 disease that did not occur at a hospital, nursing home, or adult care facility. The primary goal of publishing this dataset is to provide users with information about healthcare facility fatalities among patients with lab-confirmed COVID-19 disease.

The information in this dataset is also updated daily on the NYS COVID-19 Tracker at https://www.ny.gov/covid-19tracker.

The data source for this dataset is the daily COVID-19 survey through the New York State Department of Health (NYSDOH) Health Electronic Response Data System (HERDS). Hospitals, nursing homes, and adult care facilities are required to complete this survey daily. The information from the survey is used for statewide surveillance, planning, resource allocation, and emergency response activities. Hospitals began reporting for the HERDS COVID-19 survey in March 2020, while Nursing Homes and Adult Care Facilities began reporting in April 2020. It is important to note that fatalities related to COVID-19 disease that occurred prior to the first publication dates are also included.

The fatality numbers in this dataset are calculated by assigning age groups to each patient based on the patient age, then summing the patient fatalities within each age group, as of each reporting date. The statewide total fatality numbers are calculated by summing the number of fatalities across all age groups, by reporting date. The fatality percentages are calculated by dividing the number of fatalities in each age group by the statewide total number of fatalities, by reporting date. The fatality numbers represent the cumulative number of fatalities that have been reported as of each reporting date.

As of May 2, 2023, of 34,206 COVID-19 cases deceased in Canada, around 4,058 were aged 60 to 69 years. This statistic shows the number of COVID-19 deaths in Canada as of May 2, 2023, by age.

Mexico, one of the countries severely affected by COVID-19, accumulated more than 5. 1 all-cause excess deaths/1,000 inhabitants and 2.5 COVID-19 confirmed deaths/1,000 inhabitants, in 2 years. In this scenario of high SARS-CoV-2 circulation, we analyzed the effectiveness of the country's vaccination strategy that used 7 different vaccines from around the world, and focused on vaccinating the oldest population first. We analyzed the national dataset published by Mexican health authorities, as a retrospective cohort, separating cases, hospitalizations, deaths and excess deaths by wave and age group. We explored if the vaccination strategy was effective to limit severe COVID-19 during the active outbreaks caused by Delta and Omicron variants. Vaccination of the eldest third of the population reduced COVID-19 hospitalizations, deaths and excess deaths by 46–55% in the third wave driven by Delta SARS-CoV-2. These adverse outcomes dropped 74–85% by the fourth wave driven by Omicron, when all adults had access to vaccines. Vaccine access for the pregnant resulted in 85–90% decrease in COVID-19 fatalities in pregnant individuals and 80% decrease in infants 0 years old by the Omicron wave. In contrast, in the rest of the pediatric population that did not access vaccination before the period analyzed, COVID-19 hospitalizations increased >40% during the Delta and Omicron waves. Our analysis suggests that the vaccination strategy in Mexico has been successful to limit population mortality and decrease severe COVID-19, but children in Mexico still need access to SARS-CoV-2 vaccines to limit severe COVID-19, in particular those 1–4 years old.

As of 2023, the third leading cause of death among teenagers aged 15 to 19 years in the United States was intentional self-harm or suicide, contributing to around 17 percent of deaths among this age group. The leading cause of death at that time was unintentional injuries, contributing to around 38.6 percent of deaths, while 20.7 percent of all deaths in this age group were due to assault or homicide. Cancer and heart disease, the overall leading causes of death in the United States, are also among the leading causes of death among U.S. teenagers. Adolescent suicide in the United States In 2021, around 22 percent of students in grades 9 to 12 reported that they had seriously considered attempting suicide in the past year. Female students were around twice as likely to report seriously considering suicide compared to male students. In 2023, New Mexico had the highest rate of suicides among U.S. teenagers, with around 28 deaths per 100,000 teenagers, followed by Idaho with a rate of 22.5 per 100,000. The states with the lowest death rates among adolescents are New Jersey and New York. Mental health treatment Suicidal thoughts are a clear symptom of mental health issues. Mental health issues are not rare among children and adolescents, and treatment for such issues has become increasingly accepted and accessible. In 2021, around 15 percent of boys and girls aged 5 to 17 years had received some form of mental health treatment in the past year. At that time, around 35 percent of youths aged 12 to 17 years in the United States who were receiving specialty mental health services were doing so because they had thought about killing themselves or had already tried to kill themselves.

The time it takes for the number of COVID-19 deaths to double varies by country. The doubling rate in the United States was 139 days as of December 13, 2020. In comparison, the number of confirmed deaths in Australia doubled from 450 to 908 in the space of 117 days between August 18 and December 13, 2020.

COVID-19: We are all in this together The commitment of civilians to follow basic hygiene measures and maintain social distancing must continue. The wellbeing of populations cannot be jeopardized, and young people must also engage in the response. In Australia, the 20- to 29-year-old age group accounts for the highest number of COVID-19 cases. With lockdown restrictions lifted, many people have returned to their regular routines and jumped back into socializing. However, there are concerns about complacency and suggestions that young adults could be driving spikes in coronavirus cases.

Receive coronavirus warnings on your smartphone It is of paramount importance that countries keep a vigilant eye on the spread of the coronavirus. One way of doing so is to invest in track and trace surveillance systems. Electronic tools are not essential, but many countries are using contact-tracing smartphone apps to make the tracking of cases more efficient. In June 2020, a contact-tracing app was rolled out across Japan, and it received nearly eight million downloads in the first month. A COVID-19 alert app was also launched in Canada at the end of July 2020. The smartphone software is initially being piloted in Ontario, but it will soon be possible for people in other provinces to use the app and report a diagnosis.

In 2023, the leading causes of death for children aged one to four years in the United States were unintentional injuries and congenital malformations, deformations, and chromosomal abnormalities. At that time, around 31 percent of all deaths among these children were caused by unintentional injuries. Differences in causes of death among children by age Just as unintentional injuries are the leading cause of death among children aged one to four, it is also the leading cause of death for the age groups five to nine and 10 to 14. However, congenital malformations, deformations, and chromosomal abnormalities account for fewer deaths as children become older, while the share of deaths caused by cancer is higher among those aged five to nine and 10 to 14. In fact, cancer is the second leading cause of death among five to nine-year-olds, accounting for around 16 percent of all deaths. Sadly, the second leading cause of death among children aged 10 to 14 is intentional self-harm, with 14 percent of all deaths among those in this age group caused by suicide. Leading causes of death in the United States The leading causes of death in the United States are heart disease and malignant neoplasms. Together, these two diseases accounted for around 42 percent of all deaths in the United States in 2023. In 2023, the lifetime odds that the average person in the United States would die from heart disease was one in six, while the odds for cancer were one in seven.

BackgroundDespite children and young people (CYP) having a low risk for severe coronavirus disease 2019 (COVID-19) outcomes, there is still a degree of uncertainty related to their risk in the context of immunodeficiency or immunosuppression, primarily due to significant reporting bias in most studies, as CYP characteristically experience milder or asymptomatic COVID-19 infection and the severe outcomes tend to be overestimated.MethodsA comprehensive systematic review to identify globally relevant studies in immunosuppressed CYP and CYP in general population (defined as younger than 25 years of age) up to 31 October 2021 (to exclude vaccinated populations) was performed. Studies were included if they reported the two primary outcomes of our study, admission to intensive therapy unit (ITU) and mortality, while data on other outcomes, such as hospitalization and need for mechanical ventilation were also collected. A meta-analysis estimated the pooled proportion for each severe COVID-19 outcome, using the inverse variance method. Random effects models were used to account for interstudy heterogeneity.FindingsThe systematic review identified 30 eligible studies for each of the two populations investigated: immunosuppressed CYP (n = 793) and CYP in general population (n = 102,022). Our meta-analysis found higher estimated prevalence for hospitalization (46% vs. 16%), ITU admission (12% vs. 2%), mechanical ventilation (8% vs. 1%), and increased mortality due to severe COVID-19 infection (6.5% vs. 0.2%) in immunocompromised CYP compared with CYP in general population. This shows an overall trend for more severe outcomes of COVID-19 infection in immunocompromised CYP, similar to adult studies.InterpretationThis is the only up-to-date meta-analysis in immunocompromised CYP with high global relevance, which excluded reports from hospitalized cohorts alone and included 35% studies from low- and middle-income countries. Future research is required to characterize individual subgroups of immunocompromised patients, as well as impact of vaccination on severe COVID-19 outcomes.Systematic Review RegistrationPROSPERO identifier, CRD42021278598.

Summary This layer has been DEPRECATED (last updated 12/1/2021). Was formerly a weekly update.

The Outbreak-Associated Cases in Congregate Living data dashboard on coronavirus.maryland.gov was redesigned on 11/17/21 to align with other outbreak reporting. Visit https://opendata.maryland.gov/dataset/MD-COVID-19-Congregate-Outbreak/ey5n-qn5s to view Outbreak-Associated Cases in Congregate Living data as reported after 11/17/21.

Confirmed COVID-19 deaths among Maryland residents who live and work in congregate living facilities in Maryland for the reporting period.

Description The MD COVID-19 - Total Deaths in Congregate Facility Settings data layer is a total of deaths confirmed by a positive COVID-19 test result that have been reported to MDH in nursing homes, assisted living facilities, group homes of 10 or more and state and local facilities for the reporting period. Data are reported to MDH by local health departments, the Department of Public Safety and Correctional Services and the Department of Juvenile Services. To appear on the list, facilities report at least one confirmed case of COVID-19 over the prior 14 days. Facilities are removed from the list when health officials determine 14 days have passed with no new cases and no tests pending. The list provides a point-in-time picture of COVID-19 case activity among these facilities. Numbers reported for each facility listed reflect totals ever reported for deaths. Data are updated once weekly.

Terms of Use The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.

BackgroundThe SARS-CoV-2 pandemic remains a critical global health concern, with older adults being the most vulnerable group. Nonetheless, it is crucial to recognize that COVID-19 has caused numerous deaths in children worldwide. Emerging evidence indicates that infants and breastfeeding children, particularly those aged below one year, face a greater risk of hospitalization and mortality than older children with COVID-19.ObjectiveThis study aimed to describe the epidemiology of COVID-19 among children during the early phase of the pandemic in Ecuador.MethodsWe conducted a country-wide population-based analysis of the epidemiology of COVID-19, using incidence and mortality data reported from Ecuador between February 15, 2020 and May 14 2021. Measurements of frequency, central tendency, dispersion, and absolute differences were calculated for all categorical and continuous variables.ResultsAt least 34,001 cases (23,587 confirmed cases, 5,315 probable and 5,099 suspected) and 258 COVID-19 related deaths have been reported among children in Ecuador during the first 16 months of the pandemic. The overall incidence rate was 612 cases per 100,000 children, the mortality rate was 3 per 100,000, while the case fatality rate was 0.76%. The highest risk group for infection was children and adolescents between 15 and 19 years of age; however, the highest mortality rate occurred in children under one year of age. The largest provinces, such as Pichincha, Guavas and Manabí, were the ones that reported the highest number of cases, 27%, 12.1% and 10.8%, respectively.ConclusionsThis study is the first to report on COVID-19 epidemics among children in Ecuador. Our findings reveal that younger children have a lower risk of SARS-CoV-2 infection, but a higher risk of mortality compared to older children and adolescents. Additionally, we observed significant disparities in infection rates and outcomes among children living in rural areas, those with comorbidities, and those from indigenous ethnic groups.